From: Can urinary exosomes act as treatment response markers in prostate cancer?
Patient | Clinical Stage (all N0) | Gleason Score | Age (years) | Serum PSA ADT4 (ng/ml) | Serum PSA ADT12 (ng/ml) | Serum PSA at 6 months (ng/ml) |
---|---|---|---|---|---|---|
1 | T2b | 7 (3+4) | 66 | 10.5 | 2.10 | 1.2 |
2 | T2b | 7 (3+4) | 62 | 134.0 | 0.20 | <0.01 |
3 | T2 | 8 (3+5) | 70 | 8.3 | 1.40 | <0.1 |
4†| n/d | 7 (3+4) | 65 | 83.2 | 83.40 | †|
5 | T2c | 7 (3+4) | 69 | 95.2 | 4.10 | <0.1 |
6 | T2 | 8 (4+4) | 70 | 10.8 | 0.10 | <0.1 |
7 | T3a | 7 (3+4) | 53 | 36.5 | 7.20 | 0.3 |
8 | T3b | 6 (3+3) | 61 | 14.1 | 0.80 | 0 |
9 | T2 | 7 (4+3) | 66 | 21.1 | 0.20 | <0.1 |
10 | T2 | 8 (4+4) | 71 | 28.1 | 1.3 | n/d |